← Back to Search

Other

CXCR4 Antagonist BL-8040 for Pancreatic Cancer

Phase 2

Waitlist Available

Led By Brandon G. Smaglo, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial is testing a combination of two drugs to treat pancreatic cancer. One drug is pembrolizumab, which helps the body's immune system attack the cancer. The other drug is CXCR4 antagonist BL-8040, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligible Conditions

Pancreatic Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors 1.1

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (CXCR4 antagonist BL-8040, pembrolizumab)Experimental Treatment3 Interventions

Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

CXCR4 Antagonist BL-8040

2016

Completed Phase 2

~20

Pembrolizumab

2017

Completed Phase 2

~2010

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,971 Previous Clinical Trials

1,787,198 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,471 Total Patients Enrolled

Brandon G. Smaglo, MDPrincipal InvestigatorM.D. Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Did the Federal Drug Administration sign off on this medication research?

"There is only preliminary data supporting the safety of this drug, as it is still in Phase 2 trials."

Answered by AI

Are people currently being signed up for this experiment?

"This clinical trial is not currently recruiting patients, as indicated on clinicaltrials.gov. The trial was initially posted on December 1st, 2016 and was most recently edited on September 22nd, 2022. Although this particular study is no longer enrolling participants, there are 2292 other trials that are presently accepting patients at this time."

Answered by AI

What are Pharmacological Studies typically used to achieve?

"malignant neoplasms is most commonly treated with Pharmacological Study. Pharmacological Study can also be effective at treating other conditions like unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."

Answered by AI

How many participants are included in this research?

"Unfortunately, this particular clinical trial is no longer actively recruiting patients. The study was initially posted on December 1st, 2016 but the most recent update occurred on September 22nd, 2022. However, there are plenty of other ongoing trials; 1286 for neoplasm metastasis and 1006 under Pharmacological Study are both currently looking for participants."

Answered by AI

What are other examples of research that have been done on this medication?

"There are 1006 ongoing clinical trials researching Pharmacological Study. 123 of those active studies are in their third phase. Most of the studies for Pharmacological Study are based in Houston, Texas; however, there are 36124 locations running these types of investigations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

2016. "Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02907099.